Skip to content
Specimen Atlas of Research Peptides30 plates · MIT
PeptidesDBan atlas
← CataloguePlate V of XXX
VPlate VReviewed 2026-04-25

DSIP

Nonapeptide

also known as Delta Sleep-Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

9-amino-acid peptide first isolated from rabbit cerebral venous blood during electrically induced delta-wave sleep (Schoenenberger / Monnier, 1977). Modulates sleep-wake architecture, reduces stress response, and shows anxiolytic effects in early human studies. Limited modern RCT data; primarily used anecdotally for sleep-onset issues.

§ I

At a glance

Per dose
100–200 mcg
[schneider-1986-dsip]
Mechanistic
Human
[schneider-1986-dsip]
Half-life (est)
Hours
Route

SQ · Pre-sleep · Daily during cycle

§ II

Mechanism

Primary target — Multiple — modulates HPA axis + thalamic delta-wave generation (proposed) [schneider-1986-dsip].

Pathway — Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depth [schneider-1986-dsip].

Downstream effect — Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effect [schneider-1986-dsip].

Origin — Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenously [schneider-1986-dsip].

§ III

Dosage

Protocols described in the cited literature; not medical advice.

ParameterValue
Standard dose100–200 mcg SQ pre-sleep [schneider-1986-dsip]
FrequencyOnce daily, pre-sleep
Lower / starter dose50 mcg pre-sleep
Evidence basisHuman-mechanistic + early clinical [schneider-1986-dsip]
Duration8–12 weeks per cycle
ReconstitutionBacteriostatic water
Timing30–60 min pre-sleep
Half-lifeShort plasma; CNS effects last hours
§ III · b

Reconstitution

A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.

Inputs
The calculator does pure mass-to-volume math. It does not recommend a dose. Refer to DSIP's cited literature for protocol specifics.
Volumetric outputFig. C — reconstitution math
Volume per dose
0.100mL
≈ 10.0 units on a U-100 insulin syringe
Concentration
2500
mcg per mL
Doses per vial
20
at this dose
§ V

Adverse events

Severities follow the FDA / CTCAE convention.

Injection site reactionmild
Mild irritation
Drowsinessmild
Expected effect (intentional)
Vivid dreamsmild
Anecdotally reported
Long-term safetymoderate
Limited modern RCT data
Pregnancy / OBsevere
Avoid
Absolute contraindications
  • — Pregnancy / breastfeeding
  • — Concurrent CNS-depressant therapy without supervision
Relative contraindications
  • — Severe sleep apnoea (untreated)
  • — Concurrent benzodiazepine / opioid use
§ VI

Administration

  1. 01
    Reconstitution

    Add 1–2 mL bacteriostatic water to vial.

  2. 02
    Injection site

    SQ — abdomen. Rotate sites.

  3. 03
    Timing

    30–60 min pre-sleep.

  4. 04
    Storage

    Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

  5. 05
    Needle

    29–31G insulin syringe.

Appendix

Sources

22%

of 36 rendered claims carry a resolvable citation.

  1. [schneider-1986-dsip]
    Schneider 1986 — Stress and DSIP — sleep modulation
    Eur J Pharmacol, 1986
    Source →
Plate composed 2026-04-25 · maturity draft · schema v1 · Contributors: peptidesdb-core · 28 fields uncited — open contributions
Edit on GitHub →Read another →